AXSM - Axsome Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.6400
-0.1300 (-4.69%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.7700
Open2.8500
Bid0.00 x 800
Ask4.80 x 1400
Day's Range2.5100 - 2.8500
52 Week Range2.0500 - 5.9500
Volume204,024
Avg. Volume300,423
Market Cap78.707M
Beta (3Y Monthly)-0.56
PE Ratio (TTM)N/A
EPS (TTM)-1.13
Earnings DateMar 5, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Axsome Therapeutics to Present at Biotech Showcase 2019

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate overview at Biotech Showcase 2019 on Wednesday, January 9, 2019 at 10:00 AM Pacific Time. A live webcast and archive of the event can be viewed on the Company's website at www.axsome.com. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options.

  • ACCESSWIRE8 days ago

    Today's Research Reports on Trending Tickers: Axsome Therapeutics and Avid Bioservices

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Wall Street bounced on Monday as optimism outweighed earlier losses caused by the U.S. - China trade dispute. Analysts expect the Federal Reserve to raise ...

  • MarketWatch9 days ago

    UPDATE: Axsome Therapeutics shares soar 24% premarket on positive trial of Alzheimer's therapy

    Shares of Axsome Therapeutics Inc. surged about 24% premarket Monday, after the biotech, which specializes in therapies for central nervous system disorders, reported positive results in an interim analysis of a trial of a treatment for the agitation associated with Alzheimer's disease. An independent data monitoring committee (IDMC) recommended continuing the Phase 1/2 trial of AXS-05 and did not indicate any safety concerns. The company intends to follow the committee's recommendation. "We anticipate that implementation of the IDMC's recommendations may provide greater flexibility to our operating plans and timelines which we will evaluate in the coming weeks," Chief Executive Herriot Tabuteau said in a statement. Roughly 70% of Alzheimer's patients suffer from agitation, which can be highly upsetting for patients and caregivers. There is currently no approved treatment for the condition. Axsome shares have fallen 47% in 2018, while the S&P 500 has fallen 1.5%.

  • GlobeNewswire9 days ago

    Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a positive outcome of the interim analysis for the ADVANCE-1 Phase 2/3 trial of AXS-05 in agitation associated with Alzheimer’s disease (AD). An independent data monitoring committee (IDMC) conducted the unblinded, pre-specified interim analysis for futility.

  • GlobeNewswire28 days ago

    Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will conduct investor meetings at the upcoming 2018 Global Mizuho Investor Conference on December 3, 2018. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. The Axsome Pain and Primary Care business unit (Axsome PPC) houses Axsome’s pain and primary care assets, including AXS-02 and AX-06, and intellectual property which covers these and related product candidates and molecules being developed by Axsome and others.

  • GlobeNewswirelast month

    Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the ASCEND (Assessing Clinical Episodes in Depression) study, a Phase 2 randomized, controlled trial of AXS-05 in major depressive disorder (MDD). AXS-05 is a novel, oral, investigational medicine, consisting of dextromethorphan and bupropion, with glutamatergic, monoaminergic, and anti-inflammatory mechanisms. ASCEND is evaluating the effect of AXS-05 as compared to bupropion on the symptoms of major depressive disorder,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome.

  • Associated Presslast month

    Axsome: 3Q Earnings Snapshot

    The New York-based company said it had a loss of 31 cents per share. The company's shares closed at $3.92. A year ago, they were trading at $4.60. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) ...

  • GlobeNewswire2 months ago

    Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a research and development (R&D) day in New York City today with key opinion leaders (KOLs), to highlight AXS-05, the company’s most advanced CNS product candidate, and unmet needs in agitation associated with Alzheimer’s disease (AD). “We are honored to host two renowned leaders in the field of Alzheimer’s disease agitation research who will discuss the condition and the current treatment landscape” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Alzheimer’s disease agitation is a serious and distressing condition for which there is currently no approved treatment.

  • GlobeNewswire2 months ago

    Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy

    Narcolepsy is a serious, debilitating, neurological condition characterized by excessive daytime sleepiness and cataplexy, which is a sudden reduction or loss of muscle tone while a patient is awake. Yesterday morning, Axsome announced that it plans to initiate a Phase 2 trial of AXS-12 for the treatment of the symptoms of narcolepsy in the fourth quarter of this year with top-line results anticipated in the first half of 2019. “We are very pleased to have received Orphan Drug Designation from the FDA for AXS-12 on the heels of our recent announcement of this new CNS product candidate for the treatment of narcolepsy,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome.

  • GlobeNewswire2 months ago

    Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a conference call and webcast with slides today at 8:00 AM Eastern Time with a key opinion leader (KOL) focusing on AXS-12 (reboxetine) and unmet needs in narcolepsy. Additional information on AXS-12, the Company’s new product candidate for the treatment of the symptoms of narcolepsy can be found in a separate related release issued this morning. The call and webcast will feature a presentation from Dr. Michael J. Thorpy who will discuss the clinical features of and current treatment landscape for narcolepsy.

  • GlobeNewswire2 months ago

    Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy

    NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) --  Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its next CNS product candidate, AXS-12 (reboxetine), which the Company is developing for the treatment of narcolepsy. Narcolepsy is a serious, debilitating, orphan neurological condition characterized by excessive daytime sleepiness and cataplexy.

  • GlobeNewswire2 months ago

    Axsome Therapeutics to Present at Upcoming Investor Conferences

    Dr. Tabuteau will present a corporate overview. A live webcast of this event can be viewed on the company’s website at www.axsome.com. Dr. Tabuteau will participate in the Therapeutic Achievements for CNS Disorders panel.

  • GlobeNewswire2 months ago

    Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will focus on its growing core CNS portfolio. As a result, the Company has created Axsome Pain and Primary Care (Axsome PPC), a new business unit to house, manage, develop and enhance the value of Axsome’s non-CNS assets.

  • GlobeNewswire3 months ago

    Axsome Therapeutics Announces $8.9 Million Registered Direct Offering

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it has entered into a definitive purchase agreement with certain existing and other institutional accredited investors to purchase in a registered direct offering 2,966,667 shares of its common stock at a purchase price of $3.00 per share. Participating investors include Armistice Capital, Lincoln Park Capital, and Sio Capital Management. The net proceeds from the offering are expected to be approximately $8.8 million.

  • Simply Wall St.3 months ago

    What Does Axsome Therapeutics Inc’s (NASDAQ:AXSM) Ownership Structure Look Like?

    Every investor in Axsome Therapeutics Inc (NASDAQ:AXSM) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see Read More...

  • GlobeNewswire3 months ago

    Axsome Therapeutics to Present at Upcoming Investor Conferences

    NEW YORK, Sept. 24, 2018-- Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced that ...

  • Associated Press4 months ago

    Axsome: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 32 cents. The company's shares closed at $2.63. A year ago, they were trading at $5.70. _____ This story was generated by Automated ...

  • ACCESSWIRE4 months ago

    Axsome Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Axsome Therapeutics, Inc. (NASDAQ: AXSM ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:00 AM Eastern ...